Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 101
Inquire Before Buying

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 3, 1, 10, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Failure (Hepatic Insufficiency) - Overview
Liver Failure (Hepatic Insufficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
AVM Biotechnology LLC
Celgene Corp
Cell2B Advanced Therapeutics SA
Daewoong Co Ltd
Genentech Inc
Immune Pharmaceuticals Inc
MallInckrodt Plc
Martin Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Novartis AG
PledPharma AB
Promethera Biosciences SA
Synlogic Inc
Takeda Pharmaceutical Co Ltd
Therapure Biopharma Inc
Unicyte AG
Versantis AG
Vital Therapies Inc
Liver Failure (Hepatic Insufficiency) - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure and Alcoholic Hepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWSR-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enasidenib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ImmuneSafe - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resatorvid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silibinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP3A4 for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYNB-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trimetazidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Failure (Hepatic Insufficiency) - Dormant Projects
Liver Failure (Hepatic Insufficiency) - Discontinued Products
Liver Failure (Hepatic Insufficiency) - Product Development Milestones
Featured News & Press Releases
May 14, 2018: PledPharma has completed the recruitment for the clinical trial with Aladote
Mar 29, 2018: Martin Pharmaceuticals Receives FDA Orphan Drug Designation for LIVANTRA
Mar 28, 2018: PledPharma receives European approval of the composition of matter patent for Aladote
Dec 12, 2017: Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference
Dec 04, 2017: Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018
Oct 04, 2017: Principal investigator of Aladote study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference
Sep 14, 2017: The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group
Sep 06, 2017: Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure
Jun 08, 2017: First patient included in PledPharma's clinical trial with Aladote
Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
May 17, 2016: COMP Issued a Positive Opinion on Orphan Medicinal Product Designation for VS-01 for The Treatment of Acute Liver Failure
Feb 29, 2016: Versantis Receives Confirmation From The EMA that Its Application for Orphan Drug Designation in Acute Liver Failure Is Valid
Jan 31, 2016: Versantis Initiates the Manufacturing Scale Up of VS-01
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by AVM Biotechnology LLC, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Celgene Corp, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Daewoong Co Ltd, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by MallInckrodt Plc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Martin Pharmaceuticals Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Novartis AG, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Synlogic Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Therapure Biopharma Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Versantis AG, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2018
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Liver Failure (Hepatic Insufficiency) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global HPV Therapeutic Vaccines Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 109
    Human papilloma virus (HPV) vaccines are used to protect against HPV infections. Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs. Scope of the Report: This report focuses on the ......
  • Global Human Chorionic Gonadotropin (HCG) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 117
    Human chorionic gonadotropin (HCG) is a female hormone produced by the placenta after implantation of the egg, which is why it can be detected in a few pregnancy tests. In addition, it can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. Scope of the Report: This report focuses on the Human Chorionic Gonadotropin (HCG) in global market, especially in North America, Europe and Asi......
  • Global Imatinib Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases. Scope of the Report: This report focuses on the Imatinib Drug in global market, especially in North America, Europe and A......
  • 2018-2023 Global Novel Drug Delivery Systems Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 184
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Novel Drug Delivery Systems market for 2018-2023. Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a......
  • 2018-2023 Global Non-Radioactive Nucleic Acid Labeling Product Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Non-Radioactive Nucleic Acid Labeling Product market for 2018-2023. In recent years, non-radioactive nucleic acid labeling and detection methodologies have become available in response to a desire by researchers and their institutions to move away from the use of radioisotopes. Advancements made in the areas of chemiluminescence and fluorescence have allowe......
  • 2018-2023 Global mRNA Vaccines & Therapeutics Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 136
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global mRNA Vaccines & Therapeutics market for 2018-2023. mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensu......
  • 2018-2023 Global Compounding Pharmacy Market Report (Status and Outlook)
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 130
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Compounding Pharmacy market for 2018-2023. The traditional role of compounding pharmacies is to make drugs prescribed by doctors for specific patients with needs that can't be met by commercially available drugs. For example: A young child may need a small, liquid dose of a drug made only in adult-dosage tablets. A person may be allergic to o......
  • 2018-2023 Global Eucalyptus Oil Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 161
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Eucalyptus Oil market for 2018-2023. Eucalyptus oil is the generic name for distilled oil from the leaf of Eucalyptus, a genus of the plant family Myrtaceae native to Australia and cultivated worldwide. Eucalyptus oil is one of the most common and widely used essential oils and has a good health care effect. It is colorless or slightly yellow liquid.......
  • 2018-2023 Global Self-Monitoring Blood Glucose (SMBG) Devices Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 138
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Self-Monitoring Blood Glucose (SMBG) Devices market for 2018-2023. Self-monitoring of blood glucose (SMBG) is an important component of modern therapy for diabetes mellitus. SMBG has been recommended for people with diabetes and their health care professionals in order to achieve a specific level of glycemic control and to prevent hypoglycemia. The goal of ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs